GHRP-6 & CJC-1295 Combo Nouveaux LTD

GHRP-6 (Growth Hormone Releasing Peptide – 6) is a hexapeptide with a chain comprised of 6 amino acids. It is one of several synthetic met-enkephalin analogs that include unnatural D-amino acids that were developed for their growth hormone releasing activity and are called growth hormone secretagogues. GHRP-6 is true HGH secretagogue.

This growth hormone releasing peptide is distinct from GHRH and do not act at the GHRH receptor, but instead acts at the growth hormone secretagogue receptor, now renamed as the ghrelin receptor.

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It has D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively.

GHRP-6 & CJC-1295 are sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection (0,3% m-Cresol).

+ Mechanism of action

GHRP-6 is not an active fragment of growth hormone releasing hormone (GHRH). Which means it stimulates the body’s own secretion of HGH. Human Growth hormone has been shown in studies to promote lean body mass and reduce adiposity (fat). This growth hormone releasing peptide is distinct from GHRH and do not act the GHRH receptor, but instead acts at the growth hormone secretagogue receptor, now renamed as the gh-relin receptor.

GHRP-6’s special sequence is considered to provide a signal to the body to begin secreting Growth Hormone(GH) release while also blocking Somatostatin, a hormone that inhibits Growth Hormone release. Research studies have shown that GHRP-6 stimulation of Growth Hormone has host of beneficial effects such as decreased body fat, increased muscle, and increased strength and stamina so maximizing the production and secretion can be great addition to improved animal physical shape. Increased amounts of Growth Hormone then can cause the liver to secrete the hormone IGF-1 which has also been implicated in improving the animal body’s ability to burn fat and build muscle. Clinical cases have shown that the use of GHRP-6 was associated with increased muscle mass and a reducion of body fat.

GHRP-6 has been one of the most thoroughly studied and is believed to be acting naturally on both pituitary and hypothalamic sites (Fairhall et al. 1995). This has been demonstrated in the primary pituitary cells of rats in a time-dependent and dose-dependent manner. In another study of Fairhall et al. (1995), they concluded that the major target of the GHRP-6 in vivo is the hypothalamus after observing that the GH(Growth Hormone) release induced by the central GHRP-6 administration is guinea pigs was inhibited by the central action of somatostatin.

Futhermore, an inhibition by somatostatin with the activated GRF neurons (GRF=Growth Hormone Releasing Factor), induced by GHRP-6, was observed via receptors known to be located on or near the GRF themselves. However, it was also observed that GHRP-6 had no effect on the intracellular cAMP levels unlike that of GHRP-2. This particual experiment futher indicated that GHRP-6 is effectively stimulating GH release from somatotrophs through different receptors, the mechanisms of which are not yet known (Chan et al. 1989).

However, some researchers suggest that action and effiiency of growth hormone is dependent on the physical condition of the experimental unit. In humans for example, GH secretion decreased with obesity. This is contrary in the case of the GHRP-6 which showd increased (almost twice that of GHRP) GH responses when administered in obese patients (Cordido et al. 1993). Though obesity has shown affecting the efficiency of the hormone, it was also suggested that GHRP-6’s effects, at least at the dose-dependent manners, were found to be sex-and age-independent without being affected by the noadregenic pathways using the a2 adrenergic receptors (Penalva et al. 2008).

CJC-1295 is a long acting growth hormone releasing hormone (GHRH) analog. GHRH, also known as growth hormone releasing factor or somatocrinin, which is produced by the arcuate nucleus in the hypothalamus. It stimulates secretion of growth hormone from the pituitary gland and is released in a pulsatile manner to ultimately stimulate pulsatile release of growth hormone. The result is an increasing level of both HGH (Human Growth Hormone) and IGF-1 (Insuling-like Growth Factor).

One very important advantage of CJC-1295 is that because of its half life, which is between 10-30 minutes, the user can control the levels of HGH and IGF-1. That means you can have high levels, when you think its best for results.

The possible benefits of GHRP-6/CJC-1295 combination:

• Fat loss
• Muscle gain
• Increased strength
• Improved skin tone
• Better sleep
• More energy
• Stronger bones
• Connective tissues

+ Adverse reaction

Both GHRP-6 and CJC-1295 are generally very well tolerated by most individuals when used at the recommended dosages of about 100mcg per injection.

• Water Retention
• Tiredness
• Increased Hunger
• Head “rush” immediately after the injection
• Increased hunger

+ Instructions for reconstitution

The injection is given into the sub-cutaneous layer which includes adipose tissue (fat).

If you are using insulin syringes which have short needles, you will need to enter the skin at 90°. to the skin, otherwise you can inject as shown in the illustration above with a 29 or 30 gauge, 0.5″ needle.

+ Dosage

Recommended dosage for mixture of GHRP-6 & CJC-1295: 200mcg (0.10mg) once per day for anti-aging. Between 800-1200 mcgs, divided in two or three doses per day for muscle gain and fat loss, directed via subcutaneous injections.

+ Storage

• This product can be used not more than 3 years from the production date (see box).
• After reconstitution, may be stored for a maximum of 14 days in a refrigerator at 2°C – 8°C.
• Store vials in an upright position.
• Store in a refrigerator (2°C – 8°C). Keep in the outer carton in order to protect from light.
• For one month can be stored at room temperature.